Loading…

Selenium mitigates methotrexate‐induced testicular injury: Insights from male NMRI mice model

Background and Aim Chemotherapy, particularly with methotrexate (MTX), often elicits testicular toxicity, leading to impaired spermatogenesis and hormone imbalances. This study aimed to investigate the potential protective effects of selenium (Se) against MTX‐induced testicular injury. Materials and...

Full description

Saved in:
Bibliographic Details
Published in:Birth defects research 2024-02, Vol.116 (2), p.e2315-n/a
Main Authors: Gholami, Mohammadreza, Nemati, Afsaneh, Zarasvand, Azita Alasvand, Zendehdel, Abolfazl, Jalili, Cyrus, Rashidi, Iraj, Mansouri, Kamran, Taheri, Forough, Assadollahi, Vahideh, Gholami, Elham
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim Chemotherapy, particularly with methotrexate (MTX), often elicits testicular toxicity, leading to impaired spermatogenesis and hormone imbalances. This study aimed to investigate the potential protective effects of selenium (Se) against MTX‐induced testicular injury. Materials and Methods Male mice were divided into control, MTX, Se, and MTX + Se groups. Histopathological examination involved the preparation of testicular tissue sections using the Johnsen's tubular biopsy score (JTBS) for spermatogenesis evaluation. Biochemical tests included the assessment of testosterone, malondialdehyde (MDA), luteinizing hormone (LH), and follicle‐stimulating hormone (FSH) levels. Real‐time quantitative polymerase chain reaction (RT‐qPCR) was employed to analyze the expression of caspase 3 (casp3), tumor protein 53 (p53), B‐cell lymphoma 2 (Bcl2), and Bcl2‐associated X protein (Bax) genes. Statistical analysis was performed using ANOVA and Tukey's tests (p 
ISSN:2472-1727
2472-1727
DOI:10.1002/bdr2.2315